SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...

Baptist Health Paducah has completed its 500th WATCHMAN Left Atrial Appendage Closure device implantation, marking a ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Findings from a trial led by Cleveland Clinic show that patients with atrial fibrillation undergoing a transcatheter aortic valve replacement (TAVR) at the same time as a left atrial appendage ...

Operators come to grips with LAA contractility in observational study ...

The OPTION trial showed equivalence between Watchman FLX and oral anticoagulation in preventing stroke, systemic embolism, and all-cause death post-ablation. Subgroup analyses revealed consistent ...

Edwards Lifesciences secures FDA clearance for its ECLIPTIS Left Atrial Appendage Exclusion System, entering a competitive ...

Patients who had leakage to the left atrial appendage due to incomplete device sealing after left atrial appendage occlusion (LAAO) experienced more clotting and bleeding events within a year ...

BTIG analysts remain high on Boston Scientific (NYSE:BSX) following meetings with the company's management this week.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...